The study will assess the safety and efficacy of umbralisib in combination with ublituximab in subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL). Ublituximab will be administered through Cycle 12, while umbralisib will be administered through cycle 24. After this time, subjects will be followed for PFS.
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).